Amgen's Q2 2009 earnings call presents a generally positive short-term outlook for the company. Amgen has raised its full-year revenue and EPS guidance, reflecting improved confidence following solid Q2 results and a strategic partnership with GlaxoSmithKline for denosumab's international commercialization. The advancement of key pipeline projects, especially involving denosumab, and operational cost efficiencies lend support to a positive investor sentiment. While there are some uncertainties regarding healthcare reforms and economic conditions, the company's proactive approach and strategic moves suggest a favorable short-term impact on the stock price.

[1]